Positive: Dyne Therapeutics shows sustained functional improvements in DMD patients with DYNE-251 treatment.

From Nasdaq: 2025-03-16 21:13:51

Dyne Therapeutics Inc. shared promising long-term clinical data from its Phase 1/2 DELIVER trial of DYNE-251, showing sustained functional improvement in patients with Duchenne muscular dystrophy. Updated results will be presented at the 2025 Muscular Dystrophy Association Conference this week. Meaningful improvements were observed in functional endpoints for patients receiving both 20 mg/kg and 10 mg/kg doses of DYNE-251 over 12-18 months. The treatment also led to near-full length dystrophin expression. The safety profile of DYNE-251 remains favorable, with no new serious adverse events reported. The company aims for expedited global approval for DYNE-251, with a potential BLA submission in early 2026.



Read more at Nasdaq: Dyne : Phase 1/2 Trial Of DYNE-251 In DMD Shows Sustained Functional Improvements Through 18 Months